Elizabeth McKenna, Executive Director of Cancer Discovery at the American Association for Cancer Research, shared an article by Mansi Saxena, et al. on X:
“Now in Cancer Discovery:
PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform:
Phase I Study in Patients with Solid & Hematological Malignancies in the Adjuvant Setting – by Mansi Saxena, Tom Marron, Philip Friedlander, Alex rubinsteyn, Bhardwaj Lab, et al.”
PGV001, a multi-peptide personalized neoantigen vaccine platform: Phase I study in patients with solid and hematological malignancies in the adjuvant setting.
Authors: Mansi Saxena, et al.
